/hriana, stock.adobe.com
Berlin – Some aspects of the Rheumatoid Arthritis Disease Management Programme (DMP) deviate from current guideline recommendations or could be supplemented. This is a preliminary conclusion of the Institute for Quality and Efficiency in Healthcare (IQWiG).
On behalf of the Federal Joint Committee (G-BA), IQWiG identified current evidence-based guidelines for the treatment of rheumatoid arthritis in order to compare their recommendations with the Disease Management Program Requirements Guideline (DMP-A-RL) and to identify any discrepancies.
For the current preliminary report, the institute evaluated 239 recommendations from 13 current evidence-based guidelines.
According to the IQWiG, discrepant recommendations were identified, among other things, in the areas of therapeutic measures, comorbidities, follow-up checks and cooperation between care sectors. The institute lists psychological, psychological and psychosocial care as a complementary aspect of care that has not yet been discussed in the DMP-A-RL.
The preliminary results of the evaluation have now been published with the aim of including important arguments or information from the specialist public and all other interested parties. Comments on the preliminary report are possible until 23 August 2024.
If these questions remain unanswered, the interviewees are expected to be invited to an oral discussion on October 14, 2024. The final project report is then created. © aha/aerzteblatt.de